Meribank Biotech Co., Ltd (4724) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Meribank Biotech Co., Ltd stock TWD 22.44, price TWD 8.88, upside +152.7%, quality 33 out of 100. Rating: strongly undervalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
11‑month range 8.62 TWD – 17.35 TWD · fair‑value band 11.28 TWD – 36.45 TWD · the 8.88 TWD price screens below the 22.44 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Meribank Biotech Co. in your weekly email
Every Wednesday you see whether Meribank Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan.
Show moreShow less
The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services.
The company was founded in 2001 and is based in Taipei, Taiwan.
Stock analysis
Meribank Biotech Co., Ltd (4724) currently trades at 8.88 TWD, while our model-based Fair Value estimate is 22.44 TWD, implying the stock looks roughly 60% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 27.10 TWD per share, and 10 of the 11 models we run sit above the 8.88 TWD price.
Bear case: the Multiples group reads lowest at 12.93 TWD, and 1 of the 11 models stay below the price. Data coverage for this calculation is low.
Scenario range: 11.28 TWD (bear) to 36.45 TWD (bull), the price of 8.88 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Meribank Biotech Co., Ltd reported revenue of 472M TWD in FY2025 versus 163M TWD in FY2021, a compound +30.4%/yr. Reported net income was −81.5M TWD in FY2025.
Key figures
Market cap 852M TWD (≈ $26.0M) Micro · P/S ratio 2.11 · EPS (TTM) −1.43 TWD · Net margin −33.1% · Return on equity −11.3% · Return on assets (EBIT) −7.9% (5-year average) · Operating margin −34.9% · Revenue (TTM) 408M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).
What moves the price
The share trades about 49% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 153%, 4724 screens cheaper than that median.
Fair Value models
Bear11.28 TWDFair Value 22.44 TWDBull36.45 TWD
Price 8.88 TWD · Upside +152.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF17.44 TWD27.79 TWD60.77 TWD75
Growth DCF16.37 TWD30.97 TWD60.51 TWD74
5Y EBITDA Exit13.27 TWD23.28 TWD42.88 TWD72
All 11 models by family
DCF Models
FCF DCF17.44 TWD27.79 TWD60.77 TWD75
Owner Earnings12.03 TWD28.16 TWD62.03 TWD70
5Y Revenue Exit10.82 TWD18.34 TWD33.99 TWD69
5Y EBITDA Exit13.27 TWD23.28 TWD42.88 TWD72
10Y Revenue Exit12.58 TWD26.40 TWD34.58 TWD66
10Y EBITDA Exit14.73 TWD31.67 TWD60.59 TWD64
Multiples
EV/EBITDA11.14 TWD15.09 TWD19.03 TWD67
EV/Revenue7.34 TWD10.77 TWD14.21 TWD53
Asset-Based
NCAV (Graham)1.67 TWD2.23 TWD3.33 TWD54
Growth DCF
Growth DCF16.37 TWD30.97 TWD60.51 TWD74
Rev-Margin DCF11.20 TWD21.08 TWD40.21 TWD69
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+28.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.6%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−36.1% (2020) → −10.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −6.0% a year for the price.
Compare Meribank Biotech Co., Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside+152.7% · Top 25%
Profitability
Return on assets−2.8% · Above median
Net margin (12 months)−33.1% · Bottom 25%
Operating margin (12 months)−34.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−25.3% · Bottom 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Meribank Biotech Co., Ltd (4724) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 22.44 TWD versus a price of 8.88 TWD, about +153% upside (undervalued).
What is the fair value of 4724?
Our model-based fair value for Meribank Biotech Co., Ltd is 22.44 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 8.88 TWD.
What is the quality score of 4724?
Meribank Biotech Co., Ltd has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Meribank Biotech Co., Ltd (4724)?
Our model-based price target is the fair value of 22.44 TWD (as of Nov 3, 2026) from 11 valuation models. Cautious scenario 11.28 TWD, optimistic scenario 36.45 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Meribank Biotech Co., Ltd stock forecast for 2026?
Our models put fair value at 22.44 TWD, about +153% upside versus a price of 8.88 TWD (undervalued). Cautious scenario 11.28 TWD, optimistic scenario 36.45 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Meribank Biotech Co., Ltd (4724)?
Meribank Biotech Co., Ltd reported trailing-twelve-month revenue of about 408M TWD (latest available figure, as of Nov 3, 2026).
What growth is priced into Meribank Biotech Co., Ltd (4724)?
For today's price to be fair in a discounted-cash-flow model, Meribank Biotech Co., Ltd would have to grow free cash flow by -4.6 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +19.4 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 4724 use?
Our models discount Meribank Biotech Co., Ltd at 9.0 %: a base by market capitalisation (nano), damped by beta 0.43, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Meribank Biotech Co., Ltd that is -4.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Meribank Biotech Co., Ltd (4724) delivered so far?
Over the past 5 years revenue at Meribank Biotech Co., Ltd grew +19.4 % a year. The price currently implies free-cash-flow growth of -4.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Meribank Biotech Co., Ltd (4724) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Meribank Biotech Co., Ltd (-4.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Meribank Biotech Co., Ltd (4724)?
The free-cash-flow yield on the price is 9.92 %: that much free cash flow Meribank Biotech Co., Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Meribank Biotech Co., Ltd (4724)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Meribank Biotech Co., Ltd it is 22.44 TWD per share (as of Nov 3, 2026), against a price of 8.88 TWD. It is the blended result of 11 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Meribank Biotech Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 4724 trades below its calculated fair value: price 8.88 TWD, fair value 22.44 TWD, a gap of about +153% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4724?
No. The price is what the market pays today (8.88 TWD); the fair value is what the company's own numbers justify (22.44 TWD). For Meribank Biotech Co., Ltd the two are 13.56 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Meribank Biotech Co., Ltd worth?
The market values Meribank Biotech Co., Ltd at about 852M TWD (market capitalisation, as of Nov 3, 2026). Per share that is 8.88 TWD; our models calculate a fair value of 22.44 TWD per share.
What do the bullish and bearish scenarios say about 4724?
Our models span a range for Meribank Biotech Co., Ltd: cautious scenario 11.28 TWD, base 22.44 TWD, optimistic 36.45 TWD per share (as of Nov 3, 2026, price 8.88 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Meribank Biotech Co., Ltd (4724)?
Balance-sheet figures for Meribank Biotech Co., Ltd (as of Nov 3, 2026): return on equity −11.3%, debt of 0.12 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 4724 from its 52-week high?
Meribank Biotech Co., Ltd trades at 8.88 TWD, about 49% below its 52-week high of 17.35 TWD and 3% above the low of 8.62 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 22.44 TWD is for.
Which stocks are comparable to Meribank Biotech Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Meribank Biotech Co., Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 8.88 TWD, calculated fair value 22.44 TWD (+153%), Quality Score 33/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4724 calculated?
We run Meribank Biotech Co., Ltd through 11 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 22.44 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Meribank Biotech Co., Ltd currently trades 60% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Meribank Biotech Co., Ltd (4724)?
The closing price on Nov 6, 2026 was 8.88 TWD. Our model-based fair value is 22.44 TWD, about +153% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Meribank Biotech Co., Ltd right now?
The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (11.28 TWD). The market is more pessimistic than our downside scenario. The model range is unusually wide (11.28 TWD to 36.45 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Meribank Biotech Co., Ltd
How large is the market capitalisation of Meribank Biotech Co., Ltd (4724)?
The market capitalisation of Meribank Biotech Co., Ltd is 852M TWD (≈ $26.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Meribank Biotech Co., Ltd (4724)?
The price-to-sales ratio of Meribank Biotech Co., Ltd is 2.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Meribank Biotech Co., Ltd (4724)?
Earnings per share at Meribank Biotech Co., Ltd are −1.43 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Meribank Biotech Co., Ltd (4724)?
The net margin of Meribank Biotech Co., Ltd is −33.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Meribank Biotech Co., Ltd (4724)?
The return on equity (ROE) of Meribank Biotech Co., Ltd is −11.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Meribank Biotech Co., Ltd (4724)?
On an EBIT basis the return on assets of Meribank Biotech Co., Ltd is −7.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Meribank Biotech Co., Ltd (4724)?
The operating margin of Meribank Biotech Co., Ltd is −34.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Meribank Biotech Co., Ltd (4724)?
Revenue at Meribank Biotech Co., Ltd is growing −25.3% versus a year earlier (3y avg +37.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Meribank Biotech Co., Ltd (4724) carry?
The net debt of Meribank Biotech Co., Ltd is 65.4M TWD (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Meribank Biotech Co., Ltd in the live analysis
One click puts Meribank Biotech Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026